ReNeuron Group plc (RQE1.F)

0,0340 0,0000 (0,00%) Börsenschluss: 10:15AM CEST

ReNeuron Group plc

Pencoed Business Park
Pencoed CF35 5HY
United Kingdom
44 20 3819 8400
https://www.reneuron.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 26

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D	Executive Chairman	503,49k	N/A	1954
Mr. John Michael Hawkins A.C.A.	Company Secretary, CFO & Director	225,88k	N/A	1966
Dr. John David Sinden B.A., BA, M.A., MA, Ph.D.	Co-Founder	120,6k	N/A	1951
Ms. Suzanne Hancock	Chief Operations Officer	N/A	N/A	N/A
Dr. Randolph Corteling Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Simon Dew	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Corporate Governance

ReNeuron Group plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.